Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18547195 | 1.00 | HDAC4 (0.57) | HDAC4HDAC7HDAC5L3MBTL1SLC6A4 | |
| SCHEMBL4064082 | 0.83 | ALDH1A1 (0.56) | HDAC4HDAC7HDAC5L3MBTL1SLC6A4 | |
| SCHEMBL28575879 | 0.82 | ATM (0.51) | HDAC4HDAC7HDAC5L3MBTL1KMT2A | |
| SCHEMBL1565337 | 0.82 | L3MBTL1 (0.50) | HDAC4HDAC7HDAC5L3MBTL1SLC6A4 | |
| SCHEMBL4507146 | 0.82 | L3MBTL1 (0.50) | HDAC4HDAC7HDAC5L3MBTL1SLC6A4 | |
| SCHEMBL21787636 | 0.82 | L3MBTL1 (0.50) | HDAC4HDAC7HDAC5L3MBTL1SLC6A4 | |
| SCHEMBL1155156 | 0.82 | L3MBTL1 (0.50) | HDAC4HDAC7HDAC5L3MBTL1SLC6A4 | |
| SCHEMBL1679062 | 0.82 | L3MBTL1 (0.54) | HDAC4HDAC7HDAC5L3MBTL1SLC6A4 | |
| SCHEMBL384968 | 0.81 | ESR1 (0.58) | CNR2KMT2ACNR1ALDH1A1 | |
| SCHEMBL5282428 | 0.81 | L3MBTL1 (0.51) | L3MBTL1CNR2KMT2ACNR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| WO-2017035114-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | WO | disclosed |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-02 | — | — | US | disclosed |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2016-09-01 | — | — | US | disclosed |
| US-9283226-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2016-03-15 | — | — | US | disclosed |
| US-9283226-B2 | Pyrazole derivatives as protein kinase modulators | ASTEX THERAPEUTICS LIMITED (GB) | 2016-03-15 | — | — | US | disclosed |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LTD (GB) | 2014-09-18 | — | — | US | disclosed |
| WO-2006136821-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006136837-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
| EP-1706385-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | Astex Therapeutics Limited (GB) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005061463-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
| EP-1318983-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | Schering Corporation (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6518287-B2 | Such as 2-((1-chlorophenyl-)pyridyl-)ethylamidoethyl-imidazole for treatment ofallergies, inflammatory and central nervous system-related diseases | SCHERING CORPORATION | 2003-02-11 | — | — | US | disclosed |
| US-20020103235-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | SCHERING CORPORATION | 2002-08-01 | — | — | US | disclosed |
| WO-2002024658-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORPORATION (US) | 2002-03-28 | — | — | WO | disclosed |
| US-5210160-A | PREPARATION OF HOMOPOLYMERS OF ETHENE AND COPOLYMERS OF ETHENE WITH HIGHER A-MONOOLEFINS USING A ZIEGLER CATALYST SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 1993-05-11 | — | — | US | disclosed |
| US-4066785-A | Esters of α-hydroperoxy-bis-p-halo-phenylacetic acids | YEDA RESEARCH & DEVELOPMENT CO., LTD. (IL) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | HDAC4 1126/4885HDAC7 1451/4885HDAC5 1161/4885 |
| US-20170057929-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | HDAC4 1107/4885HDAC7 1419/4885HDAC5 1155/4885 |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | CNR1, GPR119, CNR2 | HDAC4 1107/4885HDAC7 1419/4885HDAC5 1155/4885 |
| US-20140271662-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | HDAC4 1174/4885HDAC7 972/4885HDAC5 970/4885 |
| US-20020103235-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | HRH3, HRH4, HRH2 | HDAC4 641/4885HDAC7 602/4885HDAC5 517/4885 |
| US-20160250187-A1 | PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS | GRK3, GRK2, NR0B2 | HDAC4 1174/4885HDAC7 972/4885HDAC5 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.